Treating Coronary Disease and the Impact of Endothelial Dysfunction

• Published in: Progress in cardiovascular diseases Vol. 57; no. 5; pp. 431 - 442
• Main Authors: Matsuzawa, Yasushi, Guddeti, Raviteja R, Kwon, Taek-Geun, Lerman, Lilach O, Lerman, Amir
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2015
• Subjects: Animals; Atherosclerosis; Cardiovascular; Cardiovascular Agents - therapeutic use; Cardiovascular disease; Coronary Disease - diagnosis; Coronary Disease - drug therapy; Coronary Disease - physiopathology; Coronary Vessels - drug effects; Coronary Vessels - physiopathology; Diagnostic Techniques, Cardiovascular; Endothelial function; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiopathology; Humans; Precision Medicine; Predictive Value of Tests; Prognosis; Treatment Outcome; Apo; apolipoprotein; ASCVD; high-density lipoprotein; myocardial infarction; RAAS; Cardiovascular disease; Endothelial function; glucagonlike peptide-1; β adrenergic receptor blocking agent; phosphatidylinositol kinase; RH-PAT; dipeptidyl peptidase 4 inhibitor; MI; nitric oxide; cholesterol ester transfer protein; T2D; flow mediated vasodilatation; MAPK; ARB; renin–angiotensin–aldosterone system; lipoprotein-associated phospholipase A 2; angiotensin II receptor blocker; AMPK; reactive hyperemia–peripheral arterial tonometry; DPP4-I; CETP; NO; Prognosis; Lp-PLA 2; atherosclerotic cardiovascular disease; DHP; 5’ adenosine monophosphate-activated protein kinase; βB; mitogen-activated protein kinase; HDL; acute coronary syndrome; LDL; angiotensin converting enzyme inhibitor; PI-3 K; Atherosclerosis; ACEI; FMD; CCB; GLP-1; cardiovascular; dihydropyridine; low-density lipoprotein; ACS; CV; type 2 diabetes; calcium channel blocker; coronary heart disease; CHD; PI-3K; Lp-PLA2
• ISSN: 0033-0620; 1532-8643; 1873-1740
• DOI: 10.1016/j.pcad.2014.10.004

Abstract Ischemic heart disease is the leading cause of morbidity and mortality throughout the world. Many clinical trials have suggested that lifestyle and pharmacologic interventions are effective in attenuating atherosclerotic disease progression and events development. However, an individualized approach with careful consideration to comprehensive vascular health is necessary to perform successful intervention strategies. Endothelial dysfunction plays a pivotal role in the early stage of atherosclerosis and is also associated with plaque progression and occurrence of atherosclerotic complications. The assessment of endothelial function provides us with important information about individual patient risk, progress and vulnerability of disease, and guidance of therapy. Thus, the application of endothelial function assessment might enable clinicians to innovate ideal individualized medicine. In this review, we summarize the current knowledge on the impact of pharmacological therapies for atherosclerotic cardiovascular disease on endothelial dysfunction, and argue for the utility of non-invasive assessment of endothelial function aiming at individualized medicine.